Article

Palmer, Rex A., Potter, Brian S., Leach, Michael J. ORCID: https://orcid.org/0000-0002-9859-1325, Jenkins, Terence C. and Chowdhry, Babur Z. (2010) An absolute structure template for a unique voltage-gated sodium channel binding site. MedChemComm, 1 (1). pp. 45-49. ISSN 2040-2503 (Print), 2040-2511 (Online) (doi:10.1039/C0MD00043D)

Palmer, Rex A., Potter, Brian S., Helliwell, Madeleine, Leach, Michael J. ORCID: https://orcid.org/0000-0002-9859-1325 and Chowdhry, Babur Z. (2008) Central nervous system drugs: Low temperature X-ray structures of (I) the base 5-(2,3-dichlorophenyl)-2,4-diamino-6-fluoromethyl-pyrimidine (4030W92) and (II) 5-(2,6-dichlorophenyl)-1-H-2,4-diamino-6-methyl-pyrimidine methanesulphonic acid salt (227C89). Journal of Chemical Crystallography, 39 (1). pp. 36-41. ISSN 1074-1542 (Print), 1572-8854 (Online) (doi:10.1007/s10870-008-9428-5)

Palmer, Rex A., Potter, Brian S., Leach, Michael J. ORCID: https://orcid.org/0000-0002-9859-1325 and Chowdhry, Babur Z. (2008) X-ray crystallographic structures of two lamotrigine analogues: (I) 3,5-diamino-6-(2-chlorophenyl)-1,2,4-triazine water solvate and (II) 3,5-diamino-6-(3,6-dichlorophenyl)-1,2,4-triazine methanol solvate. Journal of Chemical Crystallography, 38 (5). pp. 387-392. ISSN 1074-1542 (Print), 1572-8854 (Online) (doi:10.1007/s10870-008-9320-3)

Palmer, Rex A., Potter, Brian S., Leach, Michael J. ORCID: https://orcid.org/0000-0002-9859-1325 and Chowdhry, Babur Z. (2008) Low temperature X-ray crystallographic structures of two lamotrigine analogues: (I) 2-methyl,3-amino, 5-imino-6-(2,3-dichlorophenyl)-1,2,4-triazine water solvate and (II) 2-methyl,3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine isethionate, hemi-hydrate. Journal of Chemical Crystallography, 38 (4). pp. 255-260. ISSN 1074-1542 (Print), 1572-8854 (Online) (doi:10.1007/s10870-008-9318-x)

Palmer, Rex A., Potter, Brian S., Leach, Michael J. ORCID: https://orcid.org/0000-0002-9859-1325 and Chowdhry, Babur Z. (2008) Low temperature X-ray structures of two crystalline forms (I) and (II) of the pyrimidine derivative and sodium channel blocker BW1003C87: 5-(2,3,5-trichlorophenyl)-2,4-diaminopyrimidine. Journal of Chemical Crystallography, 38 (6). pp. 407-411. ISSN 1074-1542 (Print), 1572-8854 (Online) (doi:10.1007/s10870-008-9319-9)

Palmer, Rex A., Potter, Brian S., Leach, Michael J. ORCID: https://orcid.org/0000-0002-9859-1325 and Chowdhry, Babur Z. (2007) X-ray crystallographic structures of neuroprotective pyrimidine derivatives: (I) the mesylate salt of BW1003C87 and (II) sipatrigine base. Journal of Chemical Crystallography, 37 (11). pp. 771-777. ISSN 1074-1542 (Print), 1572-8854 (Online) (doi:10.1007/s10870-007-9248-z)

Riddall, Dieter R., Leach, Michael J. ORCID: https://orcid.org/0000-0002-9859-1325 and Garthwaite, John (2006) A novel drug binding site on voltage-gated sodium channels in rat brain. Molecular Pharmacology, 69 (1). pp. 278-287. ISSN 1521-0111 (Online) (doi:10.1124/mol.105.015966)

Patent

University of Greenwich (2010) Cyclic triazo sodium channel blockers. 12801937.

BTG International Limited (2010) Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids. PT1853254 (E).

BTG International Ltd (2009) Structured phospholipids. US2009/0036410 A1.

BTG International Limited (2008) Treatment of neurodegenerative conditions. GB2442161/B.

BTG International Limited (2006) Treatment of cytokine dysregulation by using sn-2 gamma-linolenoyl, gamma-dihomolinolenoyl or arachidonoyl patty acid glycerol monoesters. PCT/GB2006/000778.

BTG International Limited (2006) Treatment of cytokine dysregulation by using sn-2 gamma-linolenoyl, gamma-dihomolinolenoyl or arachidonoyl patty acid glycerol monoesters. WO2006/092622A1.

BTG International Limited (2006) Structured phospholipids. WO2006/056783 A2.

BTG International Limited (2005) Treatment of neurodegenerative conditions. WO2005/018632/A1.

BTG International Limited (2004) Use of triglyceride oils containing gamma-linolenic residues and linoleic acid residues for the treatment of neurodegenerative disease. WO2004/100943 A1.

BTG International Limited (2004) Treatment of neurodegenerative conditions. US 2004/0229873 Al.